Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
SPRY — ARS Pharmaceuticals, Inc.
NASDAQ
FULL STOCK PAGE →

Q1 2026 Earnings Call Summary

MAY 15, 2026
REVENUE
$22.7M -19.2%
NET MARGIN
-267.3% -120.1 PTS
EPS
-$0.61 -45.2%
FREE CASH FLOW
-$44.9M -3.4%

No summary has been written for this call yet.